Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Moderna's norovirus vaccine trial paused due to a rare neurological effect, Citadel's short position in GSK, bird flu response issues during Trump's term, WHO's call for alcohol warning labels, and ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.